Metabolic decompensation in pump users due to lispro insulin precipitation

Small, short term studies show that lispro insulin (Humalog; Eli Lilly & Co, Indianapolis, IN), commonly used in pump therapy, is stable in insulin pumps. 1 However, in agreement with reports by others, 2 we have noted several patients who have developed erratic and unpredictable glucose fluctua...

Full description

Saved in:
Bibliographic Details
Published in:BMJ 2002-05, Vol.324 (7348), p.1253-1253
Main Authors: Wolpert, Howard A, Faradji, Raquel N, Bonner-Weir, Susan, Lipes, Myra A
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Case studies
Catheters
Chemical Precipitation
Diabetes
Diabetes Mellitus, Type 1 - drug therapy
Female
Glucose
Hormones. Endocrine system
Humans
Hyperglycemia
Hypoglycemia
Hypoglycemic Agents - adverse effects
Infusion Pumps, Implantable
Insulin
Insulin - adverse effects
Insulin - analogs & derivatives
Insulin Infusion Systems
Insulin Lispro
Medical sciences
Metabolism
Pharmacology. Drug treatments
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Small, short term studies show that lispro insulin (Humalog; Eli Lilly & Co, Indianapolis, IN), commonly used in pump therapy, is stable in insulin pumps. 1 However, in agreement with reports by others, 2 we have noted several patients who have developed erratic and unpredictable glucose fluctuations with lispro insulin that have resolved when the treatment was changed to buffered regular insulin (Velosulin; Novo Nordisk, Princeton, NJ) and aspart insulin (Novolog; Novo Nordisk, Princeton, NJ).
ISSN:0959-8138
0959-8146
1468-5833
1756-1833
DOI:10.1136/bmj.324.7348.1253